Hinova Pharmaceuticals Inc. (SHA:688302)
China flag China · Delayed Price · Currency is CNY
32.91
-0.15 (-0.45%)
Sep 1, 2026, 4:00 PM EDT

Hinova Pharmaceuticals Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
62.2720.470.37-1.65-
Revenue Growth
363.89%5480.11%----
Gross Profit
60.5920.190.03-0.88-
Operating Income
-159.52-173.51-227.91-336.69-347.87-345.27
Net Income
-131.62-137.25-199.5-294.16-301.51-306.18
Earnings Per Share
-1.34-1.39-2.01-2.97-3.32-4.12
EPS Growth
------

Revenue by Geography

Fiscal YearFY 2025
Period EndingDec '25
China
20.47
Overseas
0
Total
20.47

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
784.73857.93843.931,1041,568901.22
Total Debt
104.76105.899.0512.8535.763.91
Net Cash (Debt)
679.96752.04834.881,0911,532897.31
Net Cash Growth
-20.66%-9.92%-23.48%-28.79%70.74%-21.16%
Net Cash Per Share
6.937.628.4111.0216.8712.07

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-107.84-108.88-187.08-255.51-314.92-227.82
Capital Expenditures
-56.01-82.89-89.55-99.18-69.21-19.77
Free Cash Flow
-163.85-191.76-276.63-354.68-384.13-247.6
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
97.30%98.62%8.43%-53.57%-
Operating Margin
-256.15%-847.65%-62127.45%--21072.49%-
Pretax Margin
-211.35%-670.50%-54379.48%--18264.53%-
Profit Margin
-211.36%-670.51%-54382.81%--18264.53%-
FCF Margin
-263.12%-936.81%-75410.46%--23269.07%-

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
52.33237.848289.18-2418.38-